KalVista Pharmaceuticals (KALV) Presents Sebetralstat Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures gain as oil pulls back ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
October 4, 2024 12:29 PM EDTNew data show effectiveness of sebetralstat in reducing anxiety during attacks; supports need for oral on-demand option to treat attacks earlier and more often
Patient perspectives spotlight the prevalence of anxiety when faced with administering injectable on-demand therapies
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ:... More



